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Thyroid tumours are the most frequent neoplasms of the endocrine
system. The diverse spectrum of tumours and tumour-like lesions
originating from thyroid follicular cells provides an useful model
for the study of alternative pathways of epithelial tumorigenesis at
the molecular level (Hedigar et al, 1988; Farid et al, 1994).
Mutations activating the RAS proto-oncogenes represent an early
step in the pathway of follicular thyroid tumorigenesis (Lemoine
et al, 1989), whereas translocations involving the RET and TRK
oncogenes, with consequent expression of aberrant fusion proteins
as well as amplification and overexpression of the MET oncogene,
have been implicated in papillary thyroid carcinogenesis
(Bongarzone et al, 1989; Di Renzo et al, 1992). A role for tumour-
suppressor genes has also been evidenced: anaplastic carcinomas
have a high frequency of point mutations of the p53 gene, and
deletions of chromosome 3p22 have been found in follicular carci-
nomas (Fagin et al, 1993; Hermann et al, 1996). Very recently,
involvement of the PTEN/MMAC1 tumour-suppressor gene has
been linked to the 10q22–23 loss of heterozygosity (LOH)
observed in thyroid tumours of follicular histotype associated with
Cowden’s syndrome (Liaw et al, 1997).
Microsatellites are simple and abundantly distributed polymor-
phic sequence repeats that represent ‘hotspots’ for base-pairing
errors during DNA replication (Karran, 1996). A very high inci-
dence of tumour-associated microsatellite mutations, consisting of
contractions or expansions in the number of repetitive unit
sequences, was initially reported in tumours of patients with
hereditary non-polyposis colorectal cancer (HNPCC) and in a
subset of sporadic colorectal cancers (Peltomäki et al, 1993;
Thibodeau et al, 1993). HNPCC families present also extra-
colorectal malignancies, notably including endometrial, gastric
and ovarian carcinomas, but not thyroid tumours (Lynch et al,
1997). In HNPCC-associated tumours, widespread microsatellite
instability (MI) is correlated with double-hit inactivation of one of
at least four different genes, hMLH1, hMSH2, hPMS1 and hPMS2,
encoding mismatch recognition and repair (MMR) proteins
(Hemminki et al, 1994; Liu et al, 1994; Nicolaides et al, 1994).
Various degrees of MI have also been reported in colorectal and
extracolorectal cancer cell lines (Boyer et al, 1995), and in several
forms of sporadic extracolorectal tumours (Eshleman and
Markowitz, 1995; Karran, 1996). At present, the genetic base(s) of
MI in sporadic cancers are poorly defined because MMR gene
mutations have been identified only in a minority of the cases
(Konishi et al, 1996).
A limited number of studies have examined the occurrence and
the role of MI in thyroid tumours. The small series of nine cases
reported by Vermiglio et al (1995) did not exhibit any MI,
although a limited incidence of MI was observed in the larger
series of tumours and tumour-like lesions analysed by Soares et al
(1997). To explore the role of MI in thyroid carcinogenesis, we
analysed the status of ten dinucleotide repeat microsatellite loci in
a panel of 51 tumours and tumour-like lesions. We also tested the
occurrence of mutations at two coding mononucleotide repeats
within the transforming growth factor b (TGF-b) type II (TbRII)
and insulin-like growth factor II (IGF-II) (IGFIIR) receptor genes
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respectively. Mutations at these repeats result in the inactivation of
the  TbRII and/or  IGFIIR gene products and represent frequent
events in MI-positive gastrointestinal malignancies (Markowitz et
al, 1995; Myeroff et al, 1995; Parson et al, 1995; Souza et al, 1996;
Ottini et al, 1998). In the present study, widespread MI tended to
be associated with lesions of the follicular type (LiVolsi, 1990).
There were no mutations at the mononucleotide repeats within the
TbRII and IGFIIR genes. The analysis of lymph node metastases
revealed that MI may occur during thyroid tumour progression.
MATERIALS AND METHODS
Pathological samples and clinical data
Forty-eight cases of sporadic thyroid neoplasms from unrelated
patients were diagnosed, classified and staged according to the
UICC criteria (Hermanek and Sobin, 1987) by one of the authors
(FN). Forty-one fresh paired normal thyroid and tumour samples
(cases no. 1–41) were obtained from partial or total thyroidectomy
specimens surgically removed during the last 3 years at the
University ‘La Sapienza’, Rome, Italy. To minimize the possibility
of an inadvertent inclusion of normal tissue in the tumour samples
and vice versa, samples were selected from microscopically
controlled areas. The samples were promptly frozen and stored at
–80°C until DNA extraction. Seven additional cases of sporadic
thyroid tumours were retrieved from surgical pathology files
(cases AR1–AR7). Moreover, three papillary thyroid carcinomas
occurring in distinct familial adenomatous polyposis (FAP)
patients from a single FAP kindred (Civitelli et al, 1996) were also
analysed. Altogether, the 51 cases analysed comprised three follic-
ular nodules, considered as putative follicular preneoplastic
lesions (LiVolsi, 1990), seven follicular adenomas, including two
microfollicular and one trabecular variants, six Hürthle cell
adenomas, two follicular carcinomas, two Hürthle cell carci-
nomas, two anaplastic carcinomas and 29 papillary carcinomas,
two of which contained areas with follicular differentiation.
Regional lymph node metastases were analysed in five cases,
including a Hürthle cell carcinoma (AR7) with 14 distinct metas-
tases and four papillary carcinomas: case AR2, with three metas-
tases; cases AR5 and no. 11, with two metastases; and case no. 29,
with a single metastasis.
DNA extraction
Extraction of normal tissue and tumour DNA from fresh samples
was performed using standard methods (Lazzereschi et al, 1997).
For formalin-fixed, paraffin-embedded samples, sections, 5–
10 mm in thickness, were collected on glass slides and stained with
haematoxylin. After pathological review, areas of normal tissue
and tumour were marked and microdissected; where the areas of
interest could not be clearly separated from surrounding tissue,
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Figure 1 Microsatellite alterations and status of the TbRII poly-A10 and IGFIIR poly-G8 mononucleotide repeats in paired normal thyroid (N) and tumour (T)
DNAs from papillary carcinoma case no. 14 (A) and anaplastic carcinoma case no. 16 (B). A and B, corresponding to each microsatellite marker, depict a
paired genotyping that presented novel tumour-associated alleles originating from compressions or expansions of repeats. Compressions of repeats are
exemplified at D2S123 in case no. 14 and, in case no. 16, at SCZD1 and D9S145, in which instability involves both alleles, and at D11S905 and D5S1074, in
which instability is associated to loss of one allele or co-migration of both alleles. Expansions of repeats are exemplified in case no. 14 at D11S904, D11S905,
D5S1074 and D3S1611, and, in case no. 16, at D2S123. The banding pattern of the TbRII poly-A10 and IGFIIR poly-G8 sequences is normal in both thyroid
tumours (T), as compared with the respective normal thyroid controls (N) and to a mutated gastric cancer control (C)342 D Lazzereschi et al
British Journal of Cancer (1999) 79(2), 340–345 © Cancer Research Campaign 1999
was performed. Genomic DNA from microdissected paraffin-
embedded samples was extracted as previously described (Ottini et
al, 1995, 1997). One microlitre (1 ml) of DNA was used to set up
10-ml polymerase chain reactions (PCR).
Microsatellite analysis
For microsatellite typings, a two-step protocol was used consisting
of a non-radioactive external PCR, followed by a radioactive
internal PCR (nested PCR) and utilizing a 1:104 dilution of primary
PCR products as template. The following ten microsatellite dinu-
cleotide repeats were analysed: D2S123, D2S174, D3S1611,
SCZD1,  D5S1074,  D9S145,  D11S904,  D11S905,  635—636 and
D17S250. Primers, PCR mixture, cycling conditions, electro-
phoretic separation and autoradiography were as previously
described (Ottini et al, 1995). The 73-bp region encompassing the
poly-A10 repeat of the TbRII gene at nucleotides 709–718 and the
110-bp region including the poly-G8 tract of the IGFIIR gene at
nucleotides 4089–4096 were amplified by using previously
reported primer sets (Parson et al, 1995; Souza et al, 1996). The
presence of mutations was tested using mutated MI-positive gastric
cancers as positive controls (Ottini et al, 1998). PCR mixture,
cycling conditions, electrophoretic separation and autoradiography
were as previously used for MI analysis (Ottini et al, 1995).
Statistical analyses for the correlation of microsatellite alter-
ations with clinicopathological characteristics were performed
using the c2 test. The P-values were computed after combining the
fraction of cases with MI at three or more loci, versus the fraction
of cases with no evidence of MI and with MI limited to one or two
loci. Statistical significance was considered at P ≤ 0.05.
RESULTS
A series of thyroid tumours and tumour-like lesions, paired to their
associated normal tissues, was tested for MI at ten dinucleotide
repeat microsatellite loci. The same samples were also analysed
for the presence of coding repeat mutations at a poly-A10 tract
within the TbRII gene (nucleotides 709–718) and at a poly-G8 tract
within the IGFIIR gene (nucleotides 4030–4140). All MI-positive
typings were confirmed in duplicate or triplicate experiments,
using samples from independent DNA extractions. Allelic imbal-
ances were not considered in the present study.
Out of the 51 primary thyroid lesions analysed, 11 (21.5%) were
positive for MI, as identified by the presence of tumour-associated
electrophoretic mobility shifts of microsatellite alleles at one or
more loci. MI-positive samples included one out of three follicular
nodules, two out of seven follicular adenomas, 6 out of 29 papil-
lary carcinomas, one out of two follicular carcinomas and one out
of two anaplastic carcinomas. Interestingly, the three FAP-associ-
ated papillary carcinomas were MI negative.
No abnormally migrating bands indicative of mutations in the
TbRII poly-A10 and IGFIIR poly-G8 sequences were detected in
the 51 cases examined, including the five tumours with MI at three
or more loci. In spite of the absence of mutations at the TbRII
poly-A10 repeat, it is noteworthy that 7 out of 11 MI-positive cases
reported in this study, including three out of five cases with MI at
three or more loci, showed reduced TbRII expression at the RNA
and/or protein level, as demonstrated in a previous work
(Lazzereschi et al, 1997). Figure 1 shows paired normal tissue and
tumour microsatellite genotypings from two cases, papillary carci-
noma no. 14 and anaplastic carcinoma no. 16, that manifested MI
at five out of ten loci but had a normal banding pattern of the TbRII
poly-A10 and IGFIIR poly-G8 sequences compared with mutated
gastric cancer controls. Notably, anaplastic carcinoma no. 16
previously demonstrated reduced TbRII expression (Lazzereschi et
al, 1997).
The MI status of regional lymph node metastases could be
examined after microdissection of metastatic foci and compared
with that of the corresponding primary carcinoma in five cases. As
Table 1 Clinicopathological characteristics of the primary and metastatic thyroid tumours and tumour-like lesions with evidence of microsatellite instability (MI)
Code Gender/ Type TNM Clinical Size Origin of MI
no. age stage (cm) samplea
37 M/49b Follicular nodule NAc NA 1.0 T D2S123
2 M/24 Follicular adenoma NA NA 3.5 T 635/636, D2S174, D5S1074, D11S904
9 W/37b Follicular adenoma NA NA 3.0 T 635/636, D9S145, SCZD1
AR6 W/35 Follicular carcinoma T4NxMx I 3.5 T D2S123, D2S174, D3S1611, D5S1074,
D9S145, SCZD1, D11S905
AR7 M/74 Hürthle cell carcinoma T1N2Mx II NDd T–




1.2 M5 D2S174, D17S250
1 W/26 Papillary carcinoma T4N0Mx III 3.0 T 635/636
14 M/32 Papillary carcinoma T1N0Mx I < 1 T D2S123, D3S1611, D5S1074, D11S904,
D11S905
25 W/32 Papillary carcinoma T1NxMx I 0.8 T 635/636
27 M/70 Papillary carcinoma T2NxMx II 1.7 T D11S904
AR1 W/ND Papillary carcinoma T2N1Mx ND 1.2 T D9S145, D11S905
AR4 W/32 Papillary carcinoma T2NxMx I 1.2 T D11S904
AR5 M/40 Papillary carcinoma T2N1Mx I ND T –
1.2 M1 D9S145
16 W/72 Anaplastic carcinoma T4NxMx IV ND T D2S123, D5S1074, D9S145, SCZD1,
D11S905
aT, primary thyroid tumour or tumour-like lesion; M1–5, different lymph node metastases. bM, man; W, woman. cNA, not applicable. dND, not determined.Microsatellites in thyroid tumours 343
British Journal of Cancer (1999) 79(2), 340–345 © Cancer Research Campaign 1999
reported in Table 1, metastases from two MI-negative primary
cancers, a papillary and a Hürthle cell carcinoma, were MI posi-
tive. In particular, the unique lymph node metastasis of papillary
carcinoma AR5 was MI positive at D9S145, whereas 5 out of 14
metastases from Hürthle cell carcinoma AR7 demonstrated hetero-
geneous MI patterns, indicative of clonal metastatic diversity.
Figure 2 shows relevant microsatellite profiles from case AR7:
metastases designated M1, M2, M3 and M5 demonstrated MI at
one locus, corresponding to D11S905 (M1), D3S1611 (M2) and
D9S145 (M3 and M5 both sharing the same MI pattern), metas-
tasis M4 was MI positive at loci D2S174 and D17S250.
It is presently accepted that only widespread MI, defined by the
presence of instability at 30% or more of the loci analysed and
referred to as replication error-positive (RER+) phenotype, is associ-
ated with a distinct clinicopathological profile (Eshleman and
Markowitz, 1996; Karran, 1996). In the present study, 5 out of 51
(9.8%) cases of primary thyroid tumours and tumour-like lesions,
comprising two follicular adenomas, one follicular carcinoma, one
anaplastic carcinoma and one papillary carcinoma, manifested MI at
three or more loci. The remaining six MI-positive cases (11.7%),
including one solitary follicular nodule and five papillary carci-
nomas, manifested MI limited to one or two loci (Table 1). No pref-
erence for instability at any specific microsatellite locus was
observed: in fact, seven out of the ten loci analysed were altered at
the same frequency. Table 2 reports the fractions of primary tumours
and tumour-like lesions with low (one or two loci) and high (three or
more loci) MI according to a series of clinicopathological features.
MI was not exclusive to malignancies because it was detected in a
solitary follicular nodule and in two follicular adenomas. In partic-
ular, MI at three or more loci was observed in 2 out of 16 benign
lesions (12.5%) and in 3 out of 35 carcinomas (8.6%). High-level
MI (three or more loci) tended to be associated with lesions of follic-
ular type: in fact, three out of nine (33.3%) tumours with follicular
growth pattern, including two out of seven follicular adenomas and
one out of two follicular carcinomas, manifested MI at three or more
loci, versus 1 out of 29 (3.4%) papillary carcinomas (P = 0.01) and
zero out of eight Hürthle cell tumours which included six adenomas
and two carcinomas (Tables 1 and 2). Moreover, MI at three or more
loci was detected in one out of two anaplastic carcinomas, usually
considered poorly differentiated lesions of follicular lineage
(Werner and Ingbar, 1991). With regard to clinical stage, 5 out of 29
carcinomas of stages I or II manifested MI, including three cases
with MI at one or two loci and two cases with MI at three or more
loci, compared with two out of five tumours of stages III or IV,
including a papillary carcinoma with MI at one locus and an
anaplastic carcinoma with MI at three or more loci. Differences in
MI positivity in relation to patients’ gender and age or tumour size
were unremarkable.
DISCUSSION
In spite of their common origin from follicular epithelium, the
great variety of histotypes and the differences in biological
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Figure 2 Microsatellite profiles of primary tumour (T), matched normal tissue (N) and individual regional lymph node metastases (M1, M2, M3, M4, M5) from
Hürthle cell carcinoma AR7. A and B respectively show the histology and low magnification views of the samples that were individually analysed after
microdissection, C shows the banding patterns of the microsatellite markers that demonstrated MI in lymph node metastases. The primary tumour does not
show any microsatellite alteration, as compared with normal thyroid tissue. The five metastases depicted here exhibit heterogeneous MI patterns at D11S905
(M1), D3S1611 (M2), D9S145 (M3 and M5, both sharing the same pattern), D2S714 and D17S250 (M4)344 D Lazzereschi et al
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different pathways of thyroid tumorigenesis (Hedigar et al, 1988;
Werner and Ingbar, 1991). This is consistent with the existence of
alternative genetic pathways for tumour development and progres-
sion, confirmed at the molecular level by distinct gene alterations
in the papillary and in the follicular histotypes (Farid et al, 1994;
Wynford-Thomas, 1997).
Microsatellite instability is an indicator of decreased replication
fidelity of genomic DNA, which, when at multiple loci, is believed
to be associated with genetic defects that promote tumorigenesis
(Eshleman and Markowitz, 1996; Karran, 1996). Few works have
analysed the MI status of thyroid tumours and tumour-like lesions.
A preliminary analysis based on a small series of cases, tested at a
limited number of microsatellite markers, failed to evidence any MI
(Vermiglio et al, 1995), whereas a second report was suggestive of a
limited role of MI in both benign and malignant tumours and even in
non-neoplastic lesions such as goitres (Soares et al, 1997). To further
investigate the frequency and role of MI in thyroid carcinogenesis, a
panel of cases encompassing all the most common tumours and
tumour-like lesions has been examined for MI at ten dinucleotide
repeats. Overall, MI at one or more loci was found in 21.5% of
thyroid tumours, a frequency comparable to those reported for
tumours of other origins (Thibodeau et al, 1993; Eshleman and
Markowitz, 1995; Karran, 1996). Widespread MI, i.e. at 30% or
more of the loci (RER+ phenotype), was found in 9.8% of the
thyroid tumours, corresponding to 45% of all MI-positive cases.
It is noteworthy that cases with MI at multiple loci were signifi-
cantly more frequent in follicular type tumours and tumour-like
lesions relative to papillary and Hürthle cell-type tumours.
Interestingly, three FAP-associated thyroid papillary carcinomas,
occurring in carriers of a germline mutation at codon 1061 of the
adenomatous polyposis coli (APC) gene (Civitelli et al, 1996),
resulted MI negative. The occurrence of widespread MI in benign
thyroid lesions and its low frequency in papillary carcinomas were
in agreement with the results of Soares et al (1997). There were no
associations between MI status and patients’ age and gender or
tumour size.
The comparison of the microsatellite profiles of lymph node
metastases with those of primary thyroid tumours and matched
normal tissues revealed that metastases with heterogeneous MI-
positive patterns may originate from primary cancers with no
evidence of MI. As in gastrointestinal cancer and melanoma
(Shibata et al, 1996; Richetta et al, 1997), this indicates either
dominant metastatic expansion of tumour cell clones underrepre-
sented in the primary lesion, or diversification of microsatellite
alleles and clonal evolution during population doublings after
metastasization. The occurrence of MI in metastases from MI-
negative primary tumours and the presence of widespread MI in
two out of five high-stage primary carcinomas raises the possi-
bility that genomic instability at sequence repeats might be associ-
ated with tumour progression in some thyroid cancers. Further
investigations of larger series of cases are required to verify this
hypothesis.
TGF-b is the most important growth-inhibitory factor in thyroid
cells (Colletta et al, 1989), and resistance or escape from TGF-b
control could contribute to the neoplastic transformation of follic-
ular epithelium (Blaydes and Wynford-Thomas, 1996; Brattain et
al, 1996; Coppa et al, 1997). TbRII mutations could have been
responsible for the loss of TGF-b responsiveness and for the
reduced levels of TbRII mRNA and protein that we previously
found in thyroid malignancies, including cases investigated in this
study (Lazzereschi et al, 1997). Nevertheless, none of the
presently analysed 51 primary tumours and tumour-like lesions,
including the 11 MI-positive cases, revealed mutations in the
TbRII and  IGFIIR coding repeats analysed, which represent
frequent sites of inactivating mutations in MI-positive gastroin-
testinal cancer (Markowitz et al, 1995; Myeroff et al, 1995; Parson
et al, 1995; Souza et al, 1996; Ottini et al, 1998). This suggests that
in thyroid tumorigenesis loss or down-regulation of TbRII expres-
sion occurs via MI-independent mechanisms.
In conclusion, our results suggest that MI may influence the
biology of follicular thyroid tumours and tumour-like lesions and the
molecular mechanisms of progression of thyroid cancer in general.
This warrants further research on the genetic base(s) and functional
consequences of genomic instability in thyroid carcinogenesis.
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